HCA Healthcare, Inc. (HCA)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $104.25B
Last updated: Nov 17, 2026 at 11:06 AM ET
HCA Healthcare, Inc. (HCA) Stock Forecast
Analysts expect HCA Healthcare (HCA) to earn $30.16 per share in the fiscal year ending Dec 31, 2026, on revenue of $79.16B. Of 26 analysts, 15 rate the stock Buy or Strong Buy, 9 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 14 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 26 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 58% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 3.8% |
| Buy | 14 | 53.8% |
| Hold | 9 | 34.6% |
| Sell | 1 | 3.8% |
| Strong Sell | 1 | 3.8% |
- Consensus
- Hold
- Total analysts
- 26
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 3.7% and revenue estimates rise 3.2%.
- Fiscal year ending Dec 31, 2026
- $30.16
- EPS consensus, revenue $79.16B
- Fiscal year ending Dec 31, 2027
- $31.28
- EPS consensus, revenue $81.66B
- Next report
- Jan 25, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $30.16 | $29.85 to $30.43 | 18 | $79.16B | $78.63B to $79.48B | 23 |
| Dec 31, 2027 | $31.28 | $29.83 to $32.50 | 23 | $81.66B | $80.46B to $82.74B | 22 |
Quarterly Estimates
The EPS consensus falls from $8.28 for the quarter ending Dec 31, 2026 to $7.49 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $8.28 | $7.72 to $8.94 | 24 | $20.22B | $19.30B to $21.30B | 23 |
| Mar 31, 2027 | $7.49 | $6.93 to $7.94 | 13 | $19.88B | $19.66B to $20.09B | 12 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 15 upward and 12 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 14 | 3 |
| Quarter ending Mar 31, 2027 | 1 | 9 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.0% from $29.56.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $30.16 | $30.16 | $29.49 | $29.49 | $29.56 | +2.0% |
| Fiscal year ending Dec 31, 2027 | $31.28 | $31.29 | $32.02 | $32.07 | $32.16 | -2.7% |
| Quarter ending Mar 31, 2027 | $7.49 | $7.52 | $7.84 | $7.82 | $7.81 | -4.0% |
Frequently Asked Questions About HCA
What is the HCA stock forecast?
Consensus analyst estimates put HCA Healthcare's EPS at $30.16 for the fiscal year ending Dec 31, 2026, on revenue of $79.16B. The consensus rating from 26 analysts is Hold.
How do analysts rate HCA stock?
Of 26 analysts covering HCA Healthcare, 1 rates it Strong Buy, 14 Buy, 9 Hold, 1 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from HCA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $30.16, with estimates from $29.85 to $30.43 from 18 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $31.28, with estimates from $29.83 to $32.50 from 23 analysts.
What revenue do analysts expect from HCA Healthcare next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $79.16B, with estimates from $78.63B to $79.48B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $81.66B, with estimates from $80.46B to $82.74B.
How many analysts cover HCA?
26 analysts rate HCA Healthcare stock, and 18 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
HCA pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors